Ishizuka et al. also reported a strong correlation between serum levels and neutropenia toxicity in patients with HNC receiving cisplatin-based CCRT, and emphasized that decreased binding activity of albumin to metal ions at low serum albumin concentrations could result in increased cisplatin-related toxicity [6,81]. This evidence concerns the gene ALB and neutropenia.